Combretastatin A4

**Cat. No.:** HY-N2146  
**CAS No.:** 117048-59-6  
**Molecular Formula:** C\textsubscript{18}H\textsubscript{20}O\textsubscript{5}  
**Molecular Weight:** 316.35  
**Target:** Microtubule/Tubulin  
**Pathway:** Cell Cycle/DNA Damage; Cytoskeleton  
**Storage:**  
- Powder, \(-20^\circ\text{C}\), 3 years  
- Powder, \(4^\circ\text{C}\), 2 years  
- In solvent, \(-80^\circ\text{C}\), 6 months  
- In solvent, \(-20^\circ\text{C}\), 1 month

### SOLVENT & SOLUBILITY

#### In Vitro

- **DMSO:** 100 mg/mL (316.11 mM; Need ultrasonic)  
- **H\textsubscript{2}O:** < 0.1 mg/mL (insoluble)

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Solvent Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 mM</td>
<td>3.1611 mL</td>
<td>15.8053 mL</td>
<td>31.6106 mL</td>
</tr>
<tr>
<td></td>
<td>5 mM</td>
<td>0.6322 mL</td>
<td>3.1611 mL</td>
<td>6.3221 mL</td>
</tr>
<tr>
<td></td>
<td>10 mM</td>
<td>0.3161 mL</td>
<td>1.5805 mL</td>
<td>3.1611 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

1. Add each solvent one by one: **10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline**  
   
   Solubility: ≥ 3 mg/mL (9.48 mM); Clear solution  

2. Add each solvent one by one: **10% DMSO >> 90% corn oil**  
   
   Solubility: ≥ 3 mg/mL (9.48 mM); Clear solution

### BIOLOGICAL ACTIVITY

**Description**  
Combretastatin A4 is a **microtubule**-targeting agent that binds **β-tubulin** with **K\textsubscript{d}** of 0.4 µM.

**IC\textsubscript{50} & Target**  
K\textsubscript{d}: 0.4 µM (β-tubulin)

**In Vitro**  
Combretastatin A4 phosphate (≥ 50 µM) significantly increases the percentage of annexin-V-binding cells and significantly decreases forward scatter. Combretastatin A4 phosphate does not appreciably increase hemolysis. Hundred µM Combretastatin A4 phosphate significantly increases Fluo3-fluorescence. The effect of Combretastatin A4 phosphate (100 µM) on annexin-V-binding is significantly blunted, but not abolished, by removal of extracellular...
**Ca^{2+}:** Combretastatin A4 phosphate (≥ 50 µM) significantly decreases GSH abundance and ATP levels but does not significantly increase ROS or ceramide[2]. Polymersomes co-encapsulating doxorubicin-combretastatin-A4 phosphate (1:10) shows strong synergistic cytotoxicity against human nasopharyngeal epidermal carcinoma (KB) cells[3]. Pretreatment with Combretastatin A4 phosphate does not influence the amount of VM in 3-D culture as well as the expression of these key molecules[4].

| In Vivo | DBP and MBP at 30 minutes after administration are higher in rats treated with Combretastatin A4 disodium phosphate 120 mg/10 mL/kg. The toxicokinetic parameters of Combretastatin A4 phosphate and Combretastatin A4 in rats treated with Combretastatin A4 disodium phosphate 120 mg/10 mL/kg are indicated, and the values of Cmax, T1/2, and AUC0-inf for Combretastatin A4 are 156±13 µM, 5.87±1.69 h, and 89.4±10.1 h·µM, respectively[1]. In vivo, W256 tumors show marked intratumoral hypoxia after Combretastatin A4 phosphate treatment, accompanied by increased VM formation. Combretastatin A4 phosphate exhibits only a delay in tumor growth within 2 days but rapid tumor regrowth afterward. VM density is positively related to tumor volume and tumor weight at day 8. Combretastatin A4 phosphate causes hypoxia which induces VM formation in W256 tumors through HIF-1α/EphA2/PI3K/matrix metalloproteinase (MMP) signaling pathway, resulting in the consequent regrowth of the damaged tumor[4]. |

| PROTOCOL | Rats: Rats are administered a single intravenous dose of Combretastatin A4 disodium phosphate at 120 mg/10 mL/kg by bolus infusion (n=3). Blood is taken via the jugular vein and collected in heparin-coated tubes at 10 minutes and 1, 3, 6, and 24 hours after administration. Plasma is separated by centrifugation immediately after sampling. After centrifugation, an aliquot of plasma is mixed with the equivalent volume of 1% formic acid and stored at −20°C. The thawed plasma samples are purified by solid-phase extraction, and the plasma concentrations of combretastatin A4 phosphate (free base of Combretastatin A4 disodium phosphate; Combretastatin A4 phosphate) and combretastatin A4 (the metabolite of Combretastatin A4 disodium phosphate; Combretastatin A4) are determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Toxicokinetic parameters [maximum concentration (Cmax), terminal half-life (T1/2), and area under the concentration-time curve from time zero to infinity (AUC0-inf)] are obtained by non-compartmental analysis using Phoenix WinNonlin 6.3. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |


**REFERENCES**


